ADEF
DNTH icon

ABS Direct Equity Fund’s Dianthus Therapeutics DNTH Stock Holding History

ABS Direct Equity Fund’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195K Sell
97
-1,903
-95% -$166K 0.12% 95
2026
Q1 		$179K Buy
+2,000
New +$116K 0.14% 85

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

ABS Direct Equity Fund's DNTH Position: Q2 2026 in Review

ABS Direct Equity Fund reduced its Dianthus Therapeutics (DNTH) stake by 95% in Q2 2026, selling an estimated $166K and leaving 97 shares worth $195K. The position accounts for 0.12% of the portfolio, ranked #95.

ABS Direct Equity Fund first reported a position in DNTH in Q1 2026 and has held it in 2 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • ABS Direct Equity Fund held 97 shares of Dianthus Therapeutics worth $195K as of Q2 2026.
  • ABS Direct Equity Fund sold 1,903 Dianthus Therapeutics shares in Q2 2026, an estimated $166K.
  • Dianthus Therapeutics made up 0.12% of ABS Direct Equity Fund's portfolio in Q2 2026, its #95 holding.
  • ABS Direct Equity Fund first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on ABS Direct Equity Fund's 13F filing for Q2 2026, filed 13 Aug 2026.